Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Cystic Fibrosis Foundation

This article was originally published in Start Up

Executive Summary

After years of battling to drum up private sector interest in a disease that afflicts only 25,000-30,000 Americans, the Cystic Fibrosis Foundation decided to take matters into its own hands. In doing so, it is charting new territory for disease-related charities. No longer content with making only small grants to academic institutions, the foundation has cut deals with biotechs that have it looking very much like a drug or biotech company itself, including significant alliances with Aurora Biosciences and Altus Biologics.

You may also be interested in...

Venture Philanthropy: The New Venture Capital?

Non-profit organizations' growing support for industry drug development does more than fill a funding gap. It brings disease-knowledge, patient-access and an understanding of the end-market that few traditional VCs can offer.

AureoGen Biosciences Inc.

Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.


Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts